KRAS Inhibitor Daraxonrasib Shows Promise in Pancreatic Cancer

Revolution Medicines' daraxonrasib shows meaningful responses in KRAS-mutant pancreatic cancer in Phase 2 data, marking a breakthrough in a notoriously hard-to-treat disease.